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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To compare nebulizers to MDIs for bronchodilator delivery for invasively ventilated critically ill adult patients in terms of physiological
response and patient outcomes. Subgroup analyses are planned according to other ventilation and bronchodilation strategies, ventilator
settings and administration variables.
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B A C K G R O U N D
Description of the condition
Acute respiratory failure is common amongst patients who are
hospitalized with an acute exacerbation of their chronic lung dis-
ease. Where optimal medical treatment has failed to relieve symp-
toms, ventilatory support is recommended (Rodriguez-Roisin
2006). Despite advances in non-invasive ventilation strategies, a
significant proportion of patients still require invasive ventilation
to treat their acute exacerbation (Brochard 1995; Plant 2000). In
addition to invasive ventilation, inhaled bronchodilators are an
essential component of the treatment and management of this pa-
tient group (NICE 2004). Short acting beta2-agonists and iprat-
ropium are widely used tomanage symptoms associatedwith acute
exacerbations and are recommended by international guidelines
(GOLD 2008).
Description of the intervention
Bronchodilator therapy aims to resolve bronchoconstriction, de-
crease the work of breathing, potentially relieve dyspnoea (Dhand
2005) and is frequently administered to mechanically ventilated
patients (Boucher 1990). Bronchodilators for mechanically ven-
tilated patients may be administered systemically through intra-
venous infusion,or directly to the lungs through the inhalation of
an aerosol (Georgopoulos 2000). There are currently two main
methods of delivering aerosol bronchodilation which have been
adapted for use in patients receiving mechanical ventilation; neb-
ulizer and metered-dose inhaler (MDI). Nebulizers deliver bron-
chodilators to the lower respiratory tract by converting the liq-
uid drug into smaller particle droplets which can then be inhaled.
The production of an aerosol may be achieved through the use of
compressed gas, ultrasonic sound frequencies or a vibrating mesh
or plate (Dhand 2006a). MDIs contain a pressurized mixture of
active drug, surfactants, preservatives and propellants. An aerosol
is generated through the actuation of the device which results in a
high speed release of the suspension from the MDI (Jantz 1999).
Aerosol delivery offers several advantages over the systemic route,
namely painless delivery of the drug directly to the site of action,
rapid onset of drug effect and the resultant reduction in dosage
requirements (Dhand 2004; Fink 1999a). As a result, aerosol in-
halation is globally recognized as the preferred route of delivery
for bronchodilators in chronic lung diseases (GOLD 2008).
Various pharmacological agents with differing modes of action
can be deployed for bronchodilation but their overall effect - re-
laxation of the bronchial smooth muscle - is congruent (Dhand
2006a). Currently, beta2-agonists, anticholinergics and methylx-
anthines make up the three main pharmacologic classes of agents
used for bronchodilation. Methylxanthines can only be adminis-
tered via enteral or parenteral routes, whereas beta2-agonists and
anticholinergics are most frequently utilized through inhalation
(BNF 2009) and will therefore be the focus of this review.
Several narrative reviews have attempted to address the issue of
which is the most appropriate and effective route of administra-
tion of bronchodilator therapy to adult patients receivingmechan-
ical ventilation. Current guidelines endorse either mode of deliv-
ery.The suggested advantages ofMDIs have been identified as ease
of administration, increased reliability in dosing, cost effectiveness
including personnel time to administer the drug and freedom from
contamination risk (Dhand 2006a; Dhand 2007a; Dhand 1996;
Fink 1999a; Hess 1991; Hess 2002). Several reviews have con-
cluded that no apparent advantage exists for either MDI or neb-
ulizer if appropriate administration techniques and dose are uti-
lized (Coleman 1996; Dhand 2004; Dhand 2007b; Dhand 2008;
Guerin 2008; Jantz 1999; O’Doherty 1997), although the high
dose of bronchodilators needed for nebulizer deliverymay be asso-
ciated with a higher degree of cardiovascular instability (Dolovich
2005).
How the intervention might work
The success of any aerosol bronchodilation therapy is dependant
on satisfactory amounts of active drug reaching the bronchial tree
(Dolovich 2005). Aerosol deposition is known to be affected by
a number of factors, with specific considerations associated with
patients receiving mechanical ventilation that are not present in
the ambulatory demographic. These include ventilator, circuit,
drug and patient related factors (Dhand 2004). Device related
factors are also present, with choice of equipment, position in
the ventilator circuit and timing of drug delivery affecting both
nebulizers and MDIs (Fink 1999a).
The efficacy of aerosol drug delivery from nebulizers and MDIs
has been shown to be variable in patients receivingmechanical ven-
tilation. Evidence suggests that performance variability is present
both in different models of nebulizer (Loffert 1994) and between
individual units of the same model (Alvine 1992). The efficacy of
bronchodilator delivery from an MDI is also variable, dependent
on timing actuation with inspiration (Crogan 1989; Dhand 2003)
and rates of inspiratory flow (Fink 1999b). The use of nebulizers
for bronchodilator delivery may lead to hypoventilation in me-
chanically ventilated patients using older ventilator models (Beaty
1989).
Multi-center survey data on bronchodilator administration prac-
tices in mechanically ventilated neonates highlights variations in
practice, with 19% of respondent institutions using MDIs at all
times,and 43% using nebulizers exclusively (Ballard 2002). Such
figures for the adult patient demographic are not available.
Why it is important to do this review
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To date, there has not been an international systematic review to
determine which method of aerosol bronchodilator delivery sys-
tem, nebulizer or MDI, is more effective in mechanically venti-
lated adult patients. This review therefore will attempt to deter-
mine which is the most effective delivery system in terms of phys-
iological response and patient outcomes.
O B J E C T I V E S
To compare nebulizers to MDIs for bronchodilator delivery for
invasively ventilated critically ill adult patients in terms of phys-
iological response and patient outcomes. Subgroup analyses are
planned according to other ventilation and bronchodilation strate-
gies, ventilator settings and administration variables.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials (RCTs), including
randomized cross-over trials where the order of the intervention
is randomized, comparing nebulizer and MDI for aerosol bron-
chodilation in mechanically ventilated adult patients.
Types of participants
Wewill include adult patients (as defined by the trialists) receiving
invasive mechanical ventilation in critical care units. If no defi-
nition is available, we will assume the participants as being adult
unless identified as paediatric in the studies.
Types of interventions
We will exclude studies in which aerosol bronchodilation agents
are delivered via the sameMDI or nebulizer device simultaneously
with another drug group. Combination administration of bron-
chodilators of differing drug groups (for example beta2-agonists
and anticholinergics) will be allowed. We will exclude any stud-
ies in which bronchodilator agents are administered by any route
other than aerosol. Other ventilation and bronchodilation strate-
gies such as heated humidification, use of spacer devices, helium
oxygen and nitric oxide mixtures will be allowed if equally dis-
tributed between the intervention and control groups.Wewill also
exclude studies where different bronchodilation agents are used
between the intervention and control groups.
Types of outcome measures
Primary outcomes
1. Reduction in airway resistance - measured as a reduction in
additional effective resistance (1Rrs)
2. Patient outcome - mortality during critical care unit
admission
3. Patient outcome - duration of mechanical ventilation
Secondary outcomes
1. Adverse changes to haemodynamic observations
2. Reduction in wheezing
3. Freedom from contamination
4. Quality of life
5. Practitioner satisfaction including ease of use and
convenience
Search methods for identification of studies
Electronic searches
Wewill search the current issue of theCochraneCentral Register of
Controlled Trials (CENTRAL) (The Cochrane Library) (Appendix
2); OVID MEDLINE (1950 to date) (Appendix 3);OVID EM-
BASE (1980 to present) (Appendix 4); and CINAHL via EBSCO-
host (1982 to date) (Appendix 5).
Searching other resources
We will not limit the search by language or publication status.
We will contact manufacturers of MDIs and nebulizers that have
been adapted for usewithin a ventilator circuit (for example Philips
Respironics, Cardinal Health and Trudell Medical) to identify any
published, unpublished or ongoing studies which meet the inclu-
sion criteria.
Wewill review conference proceedings available online for relevant
trials (American Thoracic Society International Conference (2006
to present); European Society of Intensive Care Medicine (2003
to present); and the Respiratory Drug Delivery Conference (2000
to present)).
We will screen reference lists within relevant trials to identify any
further potential papers worthy of review.
Data collection and analysis
Selection of studies
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We will undertake the systematic review using the methods out-
lined in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2008).
Two authors (AH and LV) will independently examine the titles
and abstracts identified by the search strategy to remove any du-
plicate records and obviously irrelevant reports. We will retrieve
and evaluate the full text versions of potentially relevant studies
identified by at least one author. Two authors (AH and LV) will
independently assess each study to determine if theymeet the eligi-
bility criteria outlined above in the section Criteria for considering
studies for this review. We will resolve any disagreements by dis-
cussion between the authors (AH and LV), with a further author
(FS) acting as arbiter. We will provide details of both included and
excluded studies in the respective tables of the review.
Data extraction and management
AH and FS will extract data independently utilising a standard-
ized data extraction form based on Cochrane Anaesthesia Review
Group recommendations (see Appendix 1). We will resolve any
disagreements by discussion between the authors (AH and FS),
with a further author (LV) acting as arbiter. The data extraction
form will include the following:
• general information: author(s), title, source, contact
address, year of study, country of study, language of publication,
year of publication;
• trial characteristics: design (RCT) and risk of bias
assessment criteria as outlined below in the section Assessment of
risk of bias in included studies;
• participants: baseline characteristics (including other
ventilation and bronchodilation strategies outlined above in the
section Types of interventions), inclusion and exclusion criteria,
sample size and number of patients allocated to each
intervention group, co morbidity;
• interventions: detailed description of the comparison
devices and administration methods, bronchodilator
administered;
• outcomes: primary outcomes - reduction in airway
resistance, measured as a reduction in additional effective
resistance (1Rrs); patient outcome including mortality during
critical care unit admission and duration of mechanical
ventilation. Secondary outcomes - adverse changes to
haemodynamic observations; reduction in wheezing; freedom
from contamination; quality of life and practitioner satisfaction
including ease of use and convenience;
• other: sources of funding, conflicts of interest, unexpected
findings.
We will use the statistical package Review Manager software
RevMan 5.0, utilizing double data entry with two authors (AH
and FS) to control and correct data entry errors.
Assessment of risk of bias in included studies
We will assess the risk of bias of included studies using The
Cochrane Collaboration’s tool for assessing risk of bias as outlined
by Higgins 2008. The standard components in this tool include
adequacy of allocation generation, allocation concealment, blind-
ing, completeness of outcome data, possible selective outcome re-
porting and any other potential sources of bias. Each component
will be judged ’Yes’ for low risk of bias, ’No’ for high risk of bias or
’Unclear’. We will include a ’Risk of bias’ table as part of the ’Table
of characteristics of included studies’ and a ’Risk of bias summary’
figure which will detail all of the judgements made for all included
studies in the review.
Assessment of risk of bias will be carried out by two authors in-
dependently (AH and FS). We will resolve any disagreements by
discussion between the authors, with a further author (LV) acting
as arbiter.
Measures of treatment effect
We will use the statistical package Review Manager software
RevMan 5.0. For dichotomous outcomes, we will calculate the
risk ratio (RR). For continuous outcomes, wewill calculate a mean
difference (MD) or the standardized mean difference (SMD) with
a 95% confidence interval (CI) as appropriate.
Unit of analysis issues
Cross-over trials
Where suitable data are available from cross-over trials, we will
adopt the approach recommended by Elbourne 2002. We will
include data using results from paired analyses, where estimates
of within patient differences, means and standard errors are either
available, can be obtained from the trialists or can be calculated.
Dealing with missing data
Where data are missing, we will contact the original investigators
to request the missing data. We intend to perform intention-to-
treat (ITT) analysis for dichotomous data. For continuous data we
will perform ITT analyses if sufficient results are available from
included studies. If data are insufficient, we will undertake an
available case analysis and consider the potential impact of the
missing data in the interpretation of the results of the review (
Higgins 2008).
Assessment of heterogeneity
We will assess clinical heterogeneity using a three step approach.
We will initially assess graphical depictions of confidence inter-
vals generated by Review Manager software RevMan 5.0 for the
amount of overlap present. Statistical heterogeneity is indicated if
there is poor overlap of confidence intervals (Higgins 2008). We
4Metered dose inhalers versus nebulizers for aerosol bronchodilator delivery for adult patients receiving mechanical ventilation in critical
care units (Protocol)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
will explore the presence of heterogeneity formally using the Chi2
statistic and quantify it using the I2 statistic (Higgins 2008). We
will consider meta-analysis if studies are suitably homogenous, in
terms of clinical diversity, to provide a meaningful summary.
Assessment of reporting biases
Wewill generate funnel plots using the mean differences and stan-
dard errors for each primary outcome to visually assess the impact
of study size on treatment estimates. If more than 10 studies are
to be included in a meta-analysis, we will also use the regression
asymmetry test to test for funnel plot asymmetry as described by
Egger 1997. Where the intervention effect is measured in terms
of odds ratios for binary data, we will test funnel plot asymmetry
using the arcsine test proposed by Rücker 2008.
Data synthesis
We will combine data from parallel group and cross-over trials for
meta-analysis. In case of bias due to carry-over effect in cross-over
trials, we will incorporate data from the first time period only if
the necessary information is available. For cross-over trials when
both time periods are used and no standard deviation of the mean
difference is available, we will impute this using the correlation
coefficient from other studies. We will calculate this from as many
other studies as possible. We will analyse the results using inverse
variance meta-analysis.
We will also meta-analyse data from parallel group and cross-over
trials separately. If there is a discrepancy between the two we will
report the results separately, otherwise the results of the meta-
analyses will be reported together.
We will employ both a fixed-effect model and a random-effects
model to combine data. If there is discrepancy between the two,
we will report results from both models. If there is no discrepancy,
we will report the results from the fixed-effect model if the I2 is less
than 50%, and from the random-effects model if the I2 is equal
to or greater than 50%.
Subgroup analysis and investigation of heterogeneity
If adequate data are available relating to other ventilation and
bronchodilation strategies such as heated humidification, use of
spacer devices, helium oxygen mixtures and nitric oxide mixtures
for ventilation, wewill conduct subgroup analyses on these groups.
We will also conduct subgroup analyses on groups in which similar
ventilation settings were used, in which an inhalation chamber
was utilized in the administration process or not, and in which it is
possible to group these according to their location in the ventilator
circuit.
To estimate the impact of differing doses of bronchodilator agents,
we will perform a subgroup analysis comparing the intervention
effect in trials inwhich higher doses of bronchodilator were used to
trials in which lower doses were administered, if the data available
enable such groupings to be made.
Sensitivity analysis
We will perform a sensitivity analysis comparing the intervention
effect in trials judged to have a low risk of bias (that is, trials in
which all components of The Cochrane Collaboration’s tool for
assessing risk of bias have been judged as “Yes”) to trials which
have been judged as having a moderate to high risk of bias (that is,
trials in which one or more of the components of The Cochrane
Collaboration’s tool for assessing risk of bias have been judged as
“Unclear” or “No”).
We will perform a sensitivity analysis comparing the intervention
effect in trials that based the decision to discontinue mechani-
cal ventilation upon pre-specified standardized criteria within the
study compared to studies that based this decision on clinicians’
judgements alone. This will be done to estimate the potential for
a biased effect when the duration of mechanical ventilation is de-
termined by a subjective judgement.
We will perform a sensitivity analysis comparing the interven-
tion effect in trials that used combination administration of bron-
chodilators of differing drug groups to studies that administered a
single bronchodilator agent. This will provide an estimate of the
potential for a biased treatment effect when combination bron-
chodilator therapy is utilized.
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Appendix 1. Study quality assessment and data extraction form
Study ID Report ID Review author name
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First author Full reference
Study eligibility
Type of study
Is the study described as
randomized?
Yes Unclear No
Next question Next question Exclude
Participants
Were the participants
mechanically ventilated
and:
- defined as adult by
trialists
OR
- NOT identified as
paediatric
Yes Unclear No
Next question Next question Exclude
Interventions
Did the study contain at
least two interventions,
comparing any model of
nebuliser to MDI for
aerosol bronchodilation?
Yes Unclear No
Next question Next question Exclude
Was the dif-
ference in bronchodila-
tor delivery device the
only planned difference
between the comparison
interventions?
Yes Unclear No
Next question Next question Exclude
Were
the same bronchodila-
tory agents used in all
comparison groups?
Yes Unclear No
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(Continued)
Next question Next question Exclude
Were only bronchodila-
tors delivered during the
trial? (i.e. no other drug
groups/agents mixed in
with bronchodilator
agent/s)
Yes Unclear No
Next question Next question Exclude
Was there any combi-
nation administration of
bronchodilators of dif-
fering drug groups?
Yes Unclear No
Exclude Next question Next question
Outcomes
Did the study record air-
way responses?
Yes Unclear No
Include
Include
(subject to clarification of “unclear”
points)
Exclude
Final decision Include Unclear Exclude
If the study is to be excluded, record the reason and details to add to “Table of excluded studies”:
General information
Authors
Contact address
Country of study
Language of publication
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Any other published versions/reports of this trial?
All references to a trial need to be linked under one Study ID both on this form (p1) and in RevMan.
Code Authors Full reference Linked Study ID on p1?
(tick)
Linked Study ID in RevMan?
(tick)
A
B
C
Add other additional lines/codes as required
Trial characteristics - Risk of bias assessment
Sequence generation
Was the allocation sequence adequately generated?
Give text which enabled your decision, including page no:
“YES” if used:
· Random number table
· Computer random number generator
· Coin tossing
· Shuffling cards/envelopes
· Throwing dice
· Minimization
“No” if used non-random method such as:
· Odd / even D.O.B
· Date of admission
· Hospital/clinic number
· Clinician judgement
· Participant preference
· Lab test results
· Availability of intervention
“Unclear” if there is insufficient information to permit “Yes” or
“No” judgement
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(Continued)
Allocation concealment
Was the allocation adequately concealed?(i.e. participants/investigators enrolling participants could not foresee assignment)
Give text which enabled your decision, including page no:
“YES” if used:
· Central allocation
· Sequentially numbered containers of identical appearance
· Sequentially numbered opaque, sealed envelopes
· Or equivalent method
“No” if investigators could potentially foresee allocation such as:
· Open random allocation scheme e.g. random list
· Envelopes without safeguards e.g. unsealed, non opaque
· Alteration / rotation
· Date of birth
· Case record number
· Other unconcealed procedure
“Unclear” if there is insufficient information to permit “Yes” or
“No” judgement
Blinding of participants, personnel and outcome assessors
Was knowledge of allocated intervention adequately prevented during study?
Note: Blinding of personnel not possible with current review, but consider if a lack of blinding has potentially influenced results
Give text which enabled your decision, including page no:
“YES” if:
· No blinding, but unlikely to influence results
· Outcome assessment blinded
“No” if:
· No blinding and is likely to influence result
· Non-blinding is likely to have introduced bias
“Unclear” if there is insufficient information to permit “Yes” or
“No” judgement, OR study did not address this outcome
Incomplete outcome data
Were incomplete outcome data adequately addressed?
Give text which enabled your decision, including page no:
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(Continued)
“YES” if missing data:
· Complete - none missing
· Unlikely to be related to true outcome
· Is balances across groups
· Effect size not enough to have clinical relevance impact on
observed effect size
· Have been imputed appropriately
“No” if missing data:
· Likely to be related to true outcome
· Effect size enough to have clinical relevance impact on observed
effect size
· “as treated” analysis done with very different numbers than at
outset
· potentially inappropriate data imputation
“Unclear” if there is insufficient information to permit “Yes” or
“No” judgement OR study did not address this outcome
Selective outcome reporting
Are study reports free of selective outcome reporting?
Give text which enabled your decision, including page no:
“YES” if:
· Protocol available and pre-set outcomes are reported in pre-set
way
· No protocol, but clear published reports of all expected out-
comes, including pre-set ones
“No” if:
· Not all pre-set outcomes reported
· 1/1+ of primary outcomes reported in different methods, units,
subsets of participants to protocol
· 1/1+ primary outcomes not pre-set
· 1/1+ outcomes reported incompletely
· Report does not include key outcome which would be expected
“Unclear” if there is insufficient information to permit “Yes” or
“No” judgement
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(Continued)
Other potential threats to validity
Was the study free of anything else which may put it at risk of bias?
Give text which enabled your decision, including page no:
“YES” if:
· Appears free from other sources
“No” if other potential source of bias e.g.:
· Study design
· Stopped early
· Extreme baseline imbalance
· Claims to be fraudulent
· Other problem
“Unclear” if there is insufficient information to permit “Yes” or
“No” judgement
Cross - over trials
Consider these potential sources of bias if the study is a cross-over design
Give text which enabled your decision, including page no:
Was the design appropriate?
Order of receiving treatments randomized?
Not biased from carry-over effects?
Unbiased data available?
Trial characteristics
Participants
Age (mean, median, range)
Sex (numbers/%)
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(Continued)
Any other ventilation/bronchodilation strategies? e.g.:
· Heated humidification
· Use of spacer devices
· Helium oxygen mixtures
· Nitric oxide mixtures
Pre-existing lung pathology? e.g.:
· COPD
· Asthma
Other Include sources of funding, conflicts of interest and any
unexpected findings
Data extraction
Outcomes
Reported in study?
Airway response:
Airway resistance
(Rrs min, Rrs max, 1Rrs)
Yes / No
Patient outcome:
Mortality Yes / No
Duration of mechanical ventilation Yes / No
Adverse changes to haemodynamic observations Yes / No
Reduction in wheezing Yes / No
Freedom from contamination Yes / No
Practitioner satisfaction Yes / No
Associated cost Yes / No
Quality of life measures Yes / No
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Continuous Outcomes - RCTs
Unit of measure-
ment
Intervention Control Details if outcomes are only described
n Mean
(SD)
n Mean
(SD)
Airway
resistance
1Rrs
Rrs max
Rrs min
Duration of me-
chanical ventila-
tion
Practitioner sat-
isfaction
Continuous Outcomes - Cross over trials
Unit of
measure-
ment
Intervention Control Cross over trial data
Record all that is available in the paper
Note - it is the within patient differences that you need the
SD, standard error and CI for
n Mean
(SD)
n Mean
(SD)
SD Standard
error
CI t P value
Airway
resistance
1Rrs
Rrs max
Rrs min
Du-
ration of
mechan-
ical venti-
lation
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(Continued)
Practi-
tioner sat-
isfaction
Dichotomous Outcomes
Intervention (n)
Note: n = number of participants, NOT
number of events
Control (n)
Note: n = number of participants, NOT
number of events
Mortality - during critical care unit admis-
sion
Adverse changes to haemodynamic obser-
vations
Reduction in wheezing
Freedom from contamination
Any other relevant information about results
e.g. if data was obtained from the trialists, if results were estimated from graphs or are calculated by you (if so, state formula and
calculations)
Freehand space for actions
Please document any contact with study authors and changes here
Trial characteristics
Single/multicentre?
Country/countries
Definition used of participant eligibility
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(Continued)
How many people randomized?
Number of participants in each intervention group
Make and model of ventilator used
Ventilator settings used
Number of participants who received intended treatment
Number of participants who were analysed
Bronchodilator and make and model of each device used
Dose and frequency of administration
Detail administration process
e.g. use of spacer device, position of nebuliser/MDI in circuit,
patient positioning etc for each intervention
Duration of treatment
How was the decision to withdraw mechanical ventilation made?
(i.e. protocol, clinical judgement or a combination)
Length of follow up reported for patient outcome
Time points when measurements were taken during the study
Time points reported
Time points you are using in RevMan
Any additional information
measures to include airway resistance (Rrs min, Rrs max, 1Rrs) Remember - we are looking for recording of these outcomes; not
reporting.
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Appendix 2. Search strategy for CENTRAL, T he Cochrane Library
#1 MeSH descriptor Metered Dose Inhalers explode all trees
#2 MeSH descriptor Nebulizers and Vaporizers explode all trees
#3 MeSH descriptor Bronchodilator Agents explode all trees
#4 MeSH descriptor Administration, Inhalation explode all trees
#5 MeSH descriptor Drug Delivery Systems explode all trees
#6 MeSH descriptor Nitric Oxide explode all trees
#7 metered-dose inhaler*
#8 MDI:ti,ab
#9 Nebuliser
#10 (bronchodilat* near (therap* or strateg*))
#11 (heated near humidific*)
#12 (spacer near devic*)
#13 (helium near oxygen)
#14 ((nitric oxide or NO) near mixture*)
#15 (bronchodilator* near delivery)
#16 (aerosol near bronchodilat*)
#17 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)
#18 MeSH descriptor Respiration, Artificial explode all trees
#19 mechanical near ventilat*
#20 (#18 OR #19)
#21 (#17 AND #20)
Appendix 3. Search strategy for MEDLINE (Ovid SP)
1. exp Metered Dose Inhalers/
2. exp “Nebulizers and Vaporizers”/ or Bronchodilator Agents/
3. Administration, Inhalation/
4. Drug Delivery Systems/
5. Nitric Oxide/ad, tu, sd [Administration & Dosage, Therapeutic Use, Supply & Distribution]
6. metered-dose inhaler*.mp.
7. MDI.ti,ab.
8. Nebuliser.mp.
9. (bronchodilat* adj6 (therap* or strateg*)).mp.
10. (heated adj3 humidific*).mp.
11. (spacer adj3 devic*).mp.
12. (helium adj3 oxygen).mp.
13. ((nitric oxide or NO) adj3 mixture*).ti,ab.
14. (bronchodilator* adj3 delivery).mp.
15. (aerosol adj6 bronchodilat*).mp.
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. exp Respiration, Artificial/
18. (mechanical adj3 ventilat*).mp.
19. 18 or 17
20. 19 and 16
21 ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or clinical trials as topic.sh. or
randomly.ab. or trial.ti.) and humans.sh.
22. 21 and 20
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Appendix 4. Search strategy for EMBASE (Ovid SP)
1 exp Metered Dose Inhaler/
2 exp Nebulizer/ or exp Medical Nebulizer/
3 exp Vaporizer/
4 exp Bronchodilating Agent/
5 exp Inhalational Drug Administration/
6 exp Drug Delivery System/
7 exp Nitric Oxide/dt, ad, do, ih [Drug Therapy, Drug Administration, Drug Dose, Inhalational Drug Administration]
8 metered-dose inhaler*.mp.
9 MDI.ti,ab.
10 Nebuliser.mp.
11 (bronchodilat* adj6 (therap* or strateg*)).mp.
12 (heated adj3 humidific*).mp.
13 (spacer adj3 devic*).mp.
14 (helium adj3 oxygen).mp.
15 ((nitric oxide or NO) adj3 mixture*).ti,ab.
16 (bronchodilator* adj3 delivery).mp.
17 (aerosol adj6 bronchodilat*).mp.
18 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
19 exp Artificial Ventilation/
20 (mechanical adj3 ventilat*).mp.
21 19 or 20
22 21 and 18
Appendix 5. Search strategy for CINAHL (EBSCOhost)
S26 S19 and S25
S25 S20 or S21 or S22 or S23 or S24
S24 AB trial* or random*
S23 (MM “Multicenter Studies”)
S22 (MM “Placebos”)
S21 (MM “Double-Blind Studies”) or (MM “Single-Blind Studies”) or (MM “Triple-Blind Studies”)
S20 (MM “Random Assignment”) or (MH “Clinical Trials+”)
S19 S15 and S18
S18 S16 or S17
S17 TX mechanical and ventilat*
S16 (MH “Respiration, Artificial+”)
S15 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14
S14 TX aerosol and bronchodilat*
S13 TX bronchodilator* and delivery
S12 AB nitric oxide or NO
S11 TX helium and oxygen*
S10 AB spacer*
S9 TX heated and humidific*
S8 AB bronchodilat* and therap*
S7 TX Nebuliser
S6 TX metered-dose inhaler*
S5 (MH “Nitric Oxide”)
S4 (MH “Drug Delivery Systems+”)
S3 (MM “Administration, Inhalation”)
S2 (MH “Bronchodilator Agents+”)
S1 (MM “Nebulizers and Vaporizers”)
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